Subgroup analysis of cancer type revealed the adverse effect of elevated YAP1 on DFS in patients with ESCC (pooled HR = 1.83; 95% CI = 1.12-3.00; P < 0.001), but there was no correlation between YAP1 expression and DFS in GC or CRC patients. This evidence concerns the gene YAP1 and colorectal carcinoma.